{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:32:24Z","timestamp":1794022344620,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T00:00:00Z","timestamp":1718755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.xjidi.2024.100296","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:32:40Z","timestamp":1719448360000},"page":"100296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica"],"prefix":"10.1016","volume":"4","author":[{"given":"Alysia N.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-8363","authenticated-orcid":false,"given":"Xing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7389-3853","authenticated-orcid":false,"given":"Julia S.","family":"Lehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2240-6397","authenticated-orcid":false,"given":"Steven A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8088-9353","authenticated-orcid":false,"given":"David J.","family":"DiCaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-0919","authenticated-orcid":false,"given":"Rekha","family":"Mudappathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-2916","authenticated-orcid":false,"given":"Angelina","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-0166","authenticated-orcid":false,"given":"Jacob","family":"Kechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7913-0294","authenticated-orcid":false,"given":"Mark R.","family":"Pittelkow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6873-1705","authenticated-orcid":false,"given":"Aaron R.","family":"Mangold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1323-3220","authenticated-orcid":false,"given":"Aleksandar","family":"Sekulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2024.100296_bib1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.ccell.2015.02.002","article-title":"Smoothened variants explain the majority of drug resistance in basal cell carcinoma","volume":"27","author":"Atwood","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xjidi.2024.100296_bib2","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1093\/bioinformatics\/btx425","article-title":"CausalR: extracting mechanistic sense from genome scale data","volume":"33","author":"Bradley","year":"2017","journal-title":"Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100296_bib3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/nbt.3838","article-title":"Reproducible RNA-seq analysis using recount2","volume":"35","author":"Collado-Torres","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.xjidi.2024.100296_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jdcr.2019.11.016","article-title":"Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2024.100296_bib5","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2024.100296_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","article-title":"Drug repurposing in rare diseases: myths and reality","volume":"75","author":"Fetro","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.xjidi.2024.100296_bib7","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1073\/pnas.1915773117","article-title":"Circadian control of interferon-sensitive gene expression in murine skin","volume":"117","author":"Greenberg","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.xjidi.2024.100296_bib8","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.jaad.2021.06.848","article-title":"Necrobiosis lipoidica-associated cutaneous malignancy","volume":"86","author":"Harvey","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1001\/jamadermatol.2018.5635","article-title":"Clinical features and comorbidities of patients with necrobiosis lipoidica with or without diabetes","volume":"155","author":"Hashemi","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/ijd.16529","article-title":"Characteristics of ulcerated and non-ulcerated necrobiosis lipoidica","volume":"62","author":"Hines","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/nprot.2008.211","article-title":"Systematic and integrative analysis of large gene lists using David bioinformatics resources","volume":"4","author":"Huang da","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.xjidi.2024.100296_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2023.11.027","article-title":"Topical Ruxolitinib in the treatment of necrobiosis lipoidica: a prospective, open-label study","author":"Hwang","year":"2024","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/1471-2105-15-224","article-title":"MAP-RSeq: mayo analysis pipeline for RNA sequencing","volume":"15","author":"Kalari","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100296_bib14","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/jid.2014.28","article-title":"Transcriptome analysis of psoriasis in a large case-control sample: RNA-seq provides insights into disease mechanisms","volume":"134","author":"Li","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib15","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.3643","article-title":"A\u00a0gene network regulated by the transcription factor VGLL3 as a promoter of sex-biased autoimmune diseases","volume":"18","author":"Liang","year":"2017","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2024.100296_bib16","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.xjidi.2024.100296_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13073-022-01026-w","article-title":"A\u00a0guide for the diagnosis of rare and undiagnosed disease: beyond the exome","volume":"14","author":"Marwaha","year":"2022","journal-title":"Genome Med"},{"key":"10.1016\/j.xjidi.2024.100296_bib18","article-title":"Improvement of granulomatous skin conditions with tofacitinib in three patients: a case report","volume":"9","author":"McPhie","year":"2021","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.xjidi.2024.100296_bib19","article-title":"A\u00a0novel approach for predicting upstream regulators (PURE) that affect gene expression [published correction appears in Sci p. 2024;14:13291]","volume":"13","author":"Nguyen","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2024.100296_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jdcr.2022.08.028","article-title":"Improvement of necrobiosis lipoidica with topical Ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream","volume":"29","author":"Nugent","year":"2022","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.xjidi.2024.100296_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd.2018.52","article-title":"Unexplored therapeutic opportunities in the human genome","volume":"17","author":"Oprea","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2024.100296_bib22","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1038\/srep08580","article-title":"Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records","volume":"5","author":"Paik","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2024.100296_bib23","doi-asserted-by":"crossref","first-page":"D548","DOI":"10.1093\/nar\/gkv1048","article-title":"Signor: a database of causal relationships between biological entities","volume":"44","author":"Perfetto","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2024.100296_bib24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2024.100296_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2105-15-91","article-title":"Differential meta-analysis of RNA-seq data from multiple studies","volume":"15","author":"Rau","year":"2014","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.xjidi.2024.100296_bib26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.xjidi.2024.100296_bib27","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","article-title":"Drug repurposing for rare diseases","volume":"42","author":"Roessler","year":"2021","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.xjidi.2024.100296_bib28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaad.2021.04.034","article-title":"Clinical and morphological features of necrobiosis lipoidica","volume":"86","author":"Severson","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jaad.2021.03.026","article-title":"Comorbidities and diabetic complications in patients with necrobiosis lipoidica","volume":"86","author":"Severson","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib30","doi-asserted-by":"crossref","first-page":"D1334","DOI":"10.1093\/nar\/gkaa993","article-title":"TCRD and Pharos 2021: mining the human proteome for disease biology","volume":"49","author":"Sheils","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.xjidi.2024.100296_bib31","first-page":"96ra77","article-title":"Discovery and preclinical validation of drug indications using compendia of public gene expression data [published correction appears in Sci Transl Med 2011;3:102er7]","volume":"3","author":"Sirota","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xjidi.2024.100296_bib32","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1038\/s41467-018-06008-4","article-title":"A\u00a0systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target","volume":"9","author":"Srivastava","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.xjidi.2024.100296_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13059-014-0570-4","article-title":"Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin","volume":"16","author":"Tsoi","year":"2015","journal-title":"Genome Biol"},{"key":"10.1016\/j.xjidi.2024.100296_bib34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.jid.2018.12.018","article-title":"Atopic dermatitis is an IL-13-dominant disease with greater molecular heterogeneity compared to psoriasis","volume":"139","author":"Tsoi","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.xjidi.2024.100296_bib35","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/nmeth.4077","article-title":"OmniPath: guidelines and gateway for literature-curated signaling pathway resources","volume":"13","author":"T\u00fcrei","year":"2016","journal-title":"Nat Methods"},{"key":"10.1016\/j.xjidi.2024.100296_bib36","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.xjidi.2024.100296_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194701","article-title":"New drug candidates for treatment of atypical meningiomas: an integrated approach using gene expression signatures for drug repurposing","volume":"13","author":"Zador","year":"2018","journal-title":"PLoS One"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026724000432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T11:22:33Z","timestamp":1731756153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026724000432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2667026724000432"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100296","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Repurposing Using Molecular Network Analysis Identifies Jak as Targetable Driver in Necrobiosis Lipoidica","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2024.100296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100296"}}